Market Making agreement with Norne Securities

5/6/2013 9:02 AM EST

NattoPharma ASA has entered into a Market Making agreement with Norne Securities AS. The purpose of the agreement is to increase the liquidity of the shares of the Company. The Market Making agreement is in accordance with the standard requirements of the Oslo Stock Exchange and will take effect on 8 May 2013.

MenaQ7® Natural Vitamin K Chosen as Finalist for Nutrition Business Technology Award

4/19/2013 3:20 AM EST

OSLO, NORWAY -- NattoPharma ASA (NATTO: Oslo Axess) has announced that its product, MenaQ7Crystals brand vitamin K2 menaquinone-7 (MK-7), the leading MK-7 ingredient, has been...

NattoPharma Names Key Executive:Eric Anderson joins Vitamin K2 Leader to Develop International Markets

4/4/2013 8:31 AM EST

4th April 2013, Oslo, Norway. NattoPharma announces the appointment of Eric Anderson as Senior Vice President (SVP) Global Sales & Marketing.

NattoPharma Names Key Executive:Eric Anderson joins Vitamin K2 as Mk-7 Leader to Develop International Markets

4/3/2013 6:29 AM EST

3rd April 2013, OSLO, NORWAY – NattoPharma (NATTO: Oslo Axess) announces the appointment of Eric Anderson as Senior Vice President Global Sales & Marketing.

MenaQ7® brand Vitamin K2 Shown More Potent than K1in New Human Study

4/3/2013 3:00 AM EST

3rd April 2013 Oslo, Norway. NattoPharma announces today the publication of a new study on its proprietary MenaQ-7™ brand of Natural Vitamin K2 standardized to MK-7 content. In...

NattoPharma’s MenaQ7® to significantly reduce bone loss and risk for osteoporosis: Significant commercial opportunities

3/27/2013 4:42 AM EST

27th March 2013 Oslo, Norway. NattoPharma announced yesterday the publication of a groundbreaking new study on its proprietary MenaQ7® brand of Natural Vitamin K2 standardized to...

MenaQ7® brand Vitamin K2 intake prevents bone loss and improves bone impact strength in postmenopausal women

3/26/2013 4:28 AM EST

26th March 2013 Oslo, Norway. NattoPharma announces today the publication of a ground-breaking new study on its proprietary MenaQ7® brand of Natural Vitamin K2 standardized to...

Financial calendar 2013

11/30/2012 8:22 AM EST

Financial calendar 2013

February 28(th) 2013 - Fourth Quarter Results 2012

May 22(nd) 2013 - First Quarter Results 2013

August 27(th) 2013 - Second Quarter Results...

Vitamin K2 Containing Food Product – Patent application no. 09/850,804 (“ex-Unilver”) approved in USA September 17th 2012

9/18/2012 5:13 AM EST

NattoPharma ASA is pleased to announce that our patent application no. 09/850,804 (“ex-Unilvere”) re. “Vitamin K2 Containing Food product” has been approved and issued in USA by...

NattoPharma Announces Expansion of Product Portfolio

9/5/2012 9:26 AM EST

NattoPharma, the worldwide pioneer behind MenaQ7® and documentation of health effects of vitamin K-2, has announced it will expand its product portfolio with new products derived...

NattoPharma Strengthens Management with New CEO

8/28/2012 6:40 AM EST

OSLO, NORWAY (August 28, 2012) -- NattoPharma ASA, the worldwide innovator of MenaQ7, a proprietary and patented vitamin K2 menaquinone-7 derived from natto, has announced a key...

Scientific Opinion of health claim related to vitamin K2 and the normal function of the heart and blood vessels pursuant to Article 13(1)

6/5/2012 11:18 AM EST

Scientific Opinion on the substantiation of a health claim related to vitamin K2 and contribution to the normal function of the heart and blood vessels (ID 125, further...

MENAQ7®: 3 Year Human Study with Vitamin K2 Demonstrates That MenaQ7® Significantly Improves Bone Strength, And Prevents Cardiovascular Aging.

5/22/2012 9:54 AM EST

22nd May 2012 Oslo, Norway. NattoPharma today announces the presentation of the recently completed milestone 3-year clinical trial investigating beneficial effects of nutritional...

NattoPharma Names Vladimir Badmaev Head of R&D, Product Development

5/16/2012 6:51 AM EST

May 16, 2012, Oslo, Norway. The Board of publicly-traded company NattoPharma ASA, announces today that Vladimir Badmaev MD, PhD has accepted the appointment as Head of Research...

NattoPharma signs an Agency Agreement with Vital Solutions for Germany.

5/2/2012 3:59 AM EST

NattoPharma is pleased to announce that the company has signed an Agency Agreement with Vital Solutions for sale of MenaQ7®, the natural vitaminK2, in Germany. With this contract...

Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects.

2/2/2012 3:13 AM EST

Theuwissen E, Cranenburg EC, Knapen MH, Magdeleyns EJ, Teunissen KJ, Schurgers LJ, Smit E, Vermeer C.

Br J Nutr. 2012 Jan 31:1-6. [Epub ahead of print]

Web Link:...

Positive results on “Clinical trial on beneficial effects of long term MenaQ7® (Natural Vitamin K2) intake by postmenopausal women”

1/16/2012 1:45 AM EST

The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.

NattoPharma - last installment on Patent Sales Agreement paid Janaury 3rd 2012

1/3/2012 6:57 AM EST

“NattoPharma ASA is pleased to announce that today the company has paid the last installment on the R&D Agreement and the Consultancy Agreement dated December 6th 2006. No action...

Vitamin K2 Containing Food Product - Patent (CA 2347387) approved and issued in Canada Dec. 20th 2011

12/21/2011 2:51 AM EST

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

NattoPharma ASA is pleased to announce that our patent CA 2347387...

European Patent no EP 1728507 - notice of oppsition

12/20/2011 3:46 AM EST

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

NattoPharma has been notified today by the European Patent Office...

NattoPharma signs a Commercial Sales Agent Agreement with Wilke Resources Inc. for USA.

12/16/2011 5:13 AM EST

NattoPharma is pleased to announce that the company has signed a Commercial Sales Agent Agreement with Wilke Resources Inc. for sale of MenaQ7®, natural vitamin K2, in USA.

SEE ALL NEWS

NattoPharma ASA

youtube facebook linkedin RSS

NattoPharma ASA is a Norwegian nutraceutical company with exclusive rights to sell and market the branded ingredient MenaQ7®, Natural Vitamin K2. We are investing in clinical science to always be at the cutting edge on v...

CONTACT

Erik Tjørstad
CFO & IR Contact
0047 916 36 395
0047 400 9008

Camilla Lindberg
Marketing Manager
0047 90954793
0047 4000 9008